Boundless Bio, Inc.
BOLD Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$2.36
3.3%What Boundless Bio, Inc. does
No business description yet.
- Legal name
- Boundless Bio, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Accession · CIK
- 0001193125-26-097543
0001782303
Revenue and margins
Boundless Bio, Inc. had — of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$47.2M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Boundless Bio, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 31.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Boundless Bio, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $121M | $152M | $108M |
| Current ratio | 13.3x | 19.0x | 8.7x |
| Quick ratio | 13.3x | 19.0x | 8.7x |
| Total assets | $130M | $206M | $157M |
| Total liabilities | $9.4M | $55.8M | $58.4M |
| Shareholders' equity | −$127M | $151M | $98.7M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | ✕ | ✕ |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −2.0% | −2.7% | −6.3% |
| Altman Z'' | −14.71 | 1.92 | −2.28 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $42.6M | $55.3M | $44.8M |
| Operating income | −$54.8M | −$73.3M | −$63.6M |
| Income tax | — | $0.0M | $0.0M |
| Net income | −$49.4M | −$65.4M | −$58.2M |
| Diluted EPS | −$40.65 | −$3.85 | −$2.60 |
| Diluted shares | 0.00B | 0.02B | 0.02B |
| Cash flow | |||
| Cash from operations | −$46.9M | −$60.8M | −$46.7M |
| Capital expenditure | $0.6M | $2.5M | $0.5M |
| Free cash flow | −$47.5M | −$63.4M | −$47.2M |
| Depreciation and amortization | $1.0M | $1.1M | $1.3M |
| Stock-based compensation | $3.3M | $7.5M | $6.1M |
| Balance sheet | |||
| Cash and short-term investments | $121M | $152M | $108M |
| Current assets | $124M | $154M | $110M |
| Current liabilities | $9.4M | $8.1M | $12.5M |
| Property and equipment, net | $2.6M | $4.3M | $3.2M |
| Total assets | $130M | $206M | $157M |
| Total liabilities | $9.4M | $55.8M | $58.4M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$127M | $151M | $98.7M |
| Returns | |||
| Return on capital employed | −45.5% | −37.0% | −44.0% |
| Return on equity | — | −554.9% | −46.7% |
| Return on assets | −38.1% | −38.9% | −32.0% |
| Return on tangible equity | — | −43.4% | −59.0% |
| Growth | |||
| Share count change | — | 1,296.7% | 31.7% |
| Financial health | |||
| Current ratio | 13.3x | 19.0x | 8.7x |
| Quick ratio | 13.3x | 19.0x | 8.7x |
| Quality scores | |||
| Altman Z'' | −14.7 | 1.9 | −2.3 |
| Accruals ratio | −2.0% | −2.7% | −6.3% |
Source: SEC EDGAR XBRL filings (CIK 0001782303). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.